Immutep Limited(NASDAQ:IMMP) 
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti...
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.59
H 1.61
L 1.45
C 1.50
V 173,424
10EMA 1.50
20EMA 1.50
60EMA 1.50
120EMA 1.50
250EMA 1.50